Detalhe da pesquisa
1.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med
; 390(4): 326-337, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078508
2.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
3.
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
; 2024 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754055
4.
The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
Br J Haematol
; 204(4): 1271-1278, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37957542
5.
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Blood
; 139(5): 666-677, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34679161
6.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789260
7.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Blood
; 139(16): 2499-2511, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995350
8.
How I manage mantle cell lymphoma: indolent versus aggressive disease.
Br J Haematol
; 201(2): 185-198, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807902
9.
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Br J Haematol
; 202(1): 48-53, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951278
10.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Br J Haematol
; 202(4): 749-759, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36257914
11.
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Blood
; 137(20): 2800-2816, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33206936
12.
Real-world experience with caplacizumab in the management of acute TTP.
Blood
; 137(13): 1731-1740, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150355
13.
Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031799
14.
Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.
Haematologica
; 108(3): 785-796, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35586966
15.
CNS prophylaxis for diffuse large B-cell lymphoma.
Lancet Oncol
; 23(9): e416-e426, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055310
16.
Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.
Br J Haematol
; 198(3): 431-442, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35235226
17.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
18.
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Hematol Oncol
; 40(2): 129-159, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713475
19.
Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.
Eur J Haematol
; 109(5): 590-592, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871485
20.
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Future Oncol
; 18(36): 3961-3969, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377973